インスリンの米国市場の評価：製品タイプ別、用途別、流通チャネル別、地域別、機会、予測（2018年～2032年）

米国のインスリンの市場規模は、2024年の81億米ドルから2032年に101億7,000万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで2.89%の成長が見込まれます。市場の成長と拡大は、糖尿病患者の増加、研究開発活動への投資の増加、主要製薬企業の国内での強いプレゼンスによって支えられています。米国疾病予防管理センターの推計によると、米国では約3,800万人が糖尿病を患っています。老年人口の急速な拡大、糖尿病に対する意識の高まり、肥満の増加などが市場の需要をさらに高めています。

肥満はインスリン抵抗性を高め、血糖値の調節を困難にするため、2型糖尿病の発症リスクを高めます。米国疾病予防管理センターは、米国の成人の5人に2人以上が肥満であると推定しています。肥満率が上昇を続ける中、米国では効果的な糖尿病管理ソリューションへのニーズが高まり、市場に有利な成長機会がもたらされると予測されます。

当レポートでは、米国のインスリン市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国関税の影響

第4章 エグゼクティブサマリー

第5章 米国のインスリン市場の見通し（2018年～2032年）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 製品別
    • 速効型インスリン
    • 持効型インスリン
    • 混合型インスリン
    • バイオシミラー
    • その他
  • タイプ別
    • ヒトインスリン
    • インスリンアナログ
  • 用途別
    • 1型糖尿病
    • 2型糖尿病
  • 流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 地域別
    • 北東部
    • 中西部
    • 西部
    • 南部
  • 市場シェア分析：企業別（上位5社とその他）（金額）（2024年）
• 市場マップ分析（2024年）
  • 製品別
  • タイプ別
  • 用途別
  • 流通チャネル別
  • 地域別

第6章 需給分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場促進要因
• 市場の課題

第12章 市場動向と発展

第13章 規制枠組みとイノベーション

• 臨床試験
• 規制当局の承認

第14章 特許情勢

第15章 ケーススタディ

第16章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Novo Nordisk Inc.
  • Sanofi S.A.
  • F. Hoffmann-La Roche AG
  • Wockhardt Limited
  • Eli Lilly USA, LLC
  • Biocon Limited

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Insulin Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Insulin Market Share (%), By Product, 2018-2032F
• Figure 3. United States Insulin Market Share (%), By Type, 2018-2032F
• Figure 4. United States Insulin Market Share (%), By Application, 2018-2032F
• Figure 5. United States Insulin Market Share (%), By Distribution Channel, 2018-2032F
• Figure 6. United States Insulin Market Share (%), By Region, 2018-2032F
• Figure 7. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 10. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

United States insulin market is projected to witness a CAGR of 2.89% during the forecast period 2025-2032, growing from USD 8.10 billion in 2024 to USD 10.17 billion in 2032. The market's growth and expansion are supported by the rising cases of diabetes, increasing investments in research and development activities, and the strong presence of leading pharmaceutical companies in the country. As per the estimates of the Centers for Disease Control and Prevention, approximately 38 million people in the United States have diabetes. The rapid expansion of the geriatric population, increasing awareness about diabetes, and growing incidences of obesity are further augmenting the market's demand.

Obesity increases the risk of developing type 2 diabetes as excessive body weight adds to insulin resistance, making it difficult to regulate blood glucose levels. The Centers for Disease Control and Prevention estimates that more than 2 in 5 adults in the United States have obesity. As obesity rates continue to increase, the requirement for effective diabetes management solutions is expected to rise in the United States, providing lucrative growth opportunities for the market.

Rising Collaborations Support Market Expansion

Strategic partnerships between pharmaceutical and biotechnology companies and healthcare organizations are allowing the pooling of resources, expertise, and manufacturing capabilities, which in turn are accelerating the development and distribution of insulin therapies across the country. Furthermore, collaborations also support the introduction of innovative insulin formulations and delivery systems, allowing pharmaceutical companies to meet the diverse requirements of the patient population and expand their presence in the industry. For instance, in February 2025, Oramed Pharmaceuticals Inc. announced a joint venture with Hefei Tianhui Biotech Co., Ltd. to form OraTech Pharmaceuticals Inc. to accelerate the development and delivery of Oramed's oral insulin (ORMD-0801) and other Protein Oral Delivery (POD) technologies. With an emphasis on commercialization and development, a pipeline poised for clinical advancements, and a strong financial foothold, OraTech is expected to transform oral biologics and redefine diabetes care.

Supportive Government Policies Boost Market Growth

The introduction of supportive government policies is playing a crucial role in shaping the trajectory of the market in the United States. In response to public pressure and advocacy, several state governments and federal programs have introduced price caps on insulin. The Inflation Reduction Act of 2022, for instance, implemented a USD 35 monthly cap on insulin for Medicare beneficiaries. This has positively impacted prescription adherence and reduced emergency hospital visits due to unmanaged diabetes. For instance, in March 2023, Eli Lilly announced a 70% reduction in the list prices of its most commonly prescribed insulins and expanded its Insulin Value Program, capping out-of-pocket costs at USD 35 or less per month.

Furthermore, legislative support is also bolstering investments in domestic insulin production, including initiatives to support nonprofit insulin manufacturers.

Technological Advancements Drive Market Demand

The integration of digital tools with insulin therapy is transforming diabetes management and allowing the patient population to live a normal life. Smart insulin pens, continuous glucose monitors, and insulin pumps are enabling patients to better monitor and control their blood sugar levels. These advanced devices are connected to smartphone apps, offering real-time data sharing and decision support systems that enhance adherence and patient outcomes. Leading medical device providers are also working on launching new technologies and products to ensure patient compliance by enhancing their comfort. For instance, in April 2023, Medtronic plc received approval from the US Food and Drug Administration (FDA) for its MiniMed 780G system with the Guardian 4 sensor, marking the approval of the first system to provide meal detection technology. Such launches are allowing patients to monitor their blood glucose levels with ease and improving patient outcomes.

Online Pharmacies Expected to Witness Significant Growth

The segment's growth is supported by the evolving consumer preferences and competitive pricing and convenience offered by online pharmacies. The rising availability of telehealth services across the United States, coupled with the expansion of e-commerce platforms, further supports online pharmacies' growth. These platforms often provide lucrative discounts, home delivery, and automated prescription refills, allowing patients to manage chronic conditions such as diabetes with ease. Additionally, leading online pharmacies are focusing on enhancing the quality of the services that they provide, allowing them to hold a major share of the market. For instance, in October 2024, Amazon.com, Inc. announced plans to expand their same-day prescription delivery services to twenty more cities in the United States by the end of 2025.

Impact of the U.S. Tariffs on the United States Insulin Market

Insulin prices in the United States are expected to increase significantly following the introduction of tariffs as the manufacturers might pass the additional expenses onto the consumers, posing significant challenges for underinsured or uninsured consumers who already face high out-of-pocket costs for insulin.

The tariffs are also expected to disrupt supply chains, resulting in potential insulin availability delays, forcing manufacturers to restore their production and seek alternative sources for active pharmaceutical ingredients.

The estimated escalation in costs could potentially strain insurance and healthcare providers, resulting in reduced coverage and higher premiums for the patient population.

Key Players Landscape and Outlook

The key players in the market are focusing on partnerships and collaborations to bolster the accessibility of insulin across the United States. For instance, in March 2025, Biocon Biologics Limited, a subsidiary of Biocon Limited, partnered with Civica, Inc. to increase the affordability and accessibility of Insulin Aspart in the country. Under the agreement terms, Biocon Biologics will provide Insulin Aspart substance to Civica, which will manufacture the rapid-acting insulin analog in Virginia, United States. The latter will also commercialize the medicine in the country. Such partnerships showcase the commitment of the leading market players in ensuring the supply of life-saving medications and are expected to provide lucrative growth opportunities for the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. United States Insulin Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Rapid-Acting Insulin
    • 5.2.1.2. Long-Acting Insulin
    • 5.2.1.3. Combination Insulin
    • 5.2.1.4. Biosimilar
    • 5.2.1.5. Others
  • 5.2.2. By Type
    • 5.2.2.1. Human Insulin
    • 5.2.2.2. Insulin Analog
  • 5.2.3. By Application
    • 5.2.3.1. Type 1 Diabetes Mellitus
    • 5.2.3.2. Type 2 Diabetes Mellitus
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital Pharmacies
    • 5.2.4.2. Retail Pharmacies
    • 5.2.4.3. Online Pharmacies
  • 5.2.5. By Region
    • 5.2.5.1. Northeast
    • 5.2.5.2. Midwest
    • 5.2.5.3. West
    • 5.2.5.4. South
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product
  • 5.3.2. By Type
  • 5.3.3. By Application
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials
• 13.2. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novo Nordisk Inc.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Sanofi S.A.
  • 16.3.3. F. Hoffmann-La Roche AG
  • 16.3.4. Wockhardt Limited
  • 16.3.5. Eli Lilly USA, LLC
  • 16.3.6. Biocon Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer